Abstract: FR-PO0946
Efficacy and Safety of Mycophenolate Mofetil vs. Cyclophosphamide in Childhood-Onset Lupus Nephritis: A Systematic Review and Meta-Analysis
Session Information
- Pediatric Nephrology: Genetic Diseases, Development, Neonatal Nephrology, Glomerular Diseases, and More
October 23, 2026 | Location: Exhibit Hall A, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Pediatric Nephrology
- 1800 Pediatric Nephrology
Authors
- Mumtaz, Muhammad Husnain, Allama Iqbal Medical College, Lahore, Punjab, Pakistan
- Sheikh, Maryam Imran, Riphah International University, Islamabad, Islamabad Capital Territory, Pakistan
- Hassan, Ali, Allama Iqbal Medical College, Lahore, Punjab, Pakistan
- Qasim, Sheraz, Post Graduate Medical Institute Ameer-ud-Din Medical College, Lahore, Punjab, Pakistan
- Amin, Fahad, King Edward Medical University, Lahore, Punjab, Pakistan
- Kotak, Pari, Liaquat University of Medical & Health Sciences, Jamshoro, Sindh, Pakistan
- Arif, Aliza, Karachi Medical and Dental College, Karachi, Sindh, Pakistan
- Sheikh, Abdullah Muhammad, Jinnah Medical and Dental College, Karachi, Sindh, Pakistan
- Joy, Basil, Government Medical College Kozhikode, Kozhikode, KL, India
- Yousaf, Muhammad, Allama Iqbal Medical College, Lahore, Punjab, Pakistan
Background
This meta-analysis evaluates the comparative efficacy and safety of Mycophenolate Mofetil (MMF) versus Cyclophosphamide (CYC) to determine if one treatment offers superior clinical or renal outcomes.
Methods
A pooled analysis of clinical studies was conducted to compare MMF and CYC. Efficacy was evaluated through continuous outcomes such as estimated glomerular filtration rate (eGFR) using mean differences (MD), and dichotomous outcomes including complete remission, complete response, partial response, and no response using risk ratios (RR). Safety and disease progression were assessed by analyzing the incidence of any adverse events and end-stage renal disease (ESRD) requiring dialysis.
Results
The analysis included a total of 11 studies. There was no significant difference in eGFR at follow-up (MD = 4.61, 95% CI [-7.15, 16.36]). Complete remission rates were comparable overall (RR = 1.02, 95% CI [0.84, 1.23]), with consistent findings at both 6-month and 12-month subgroups. Furthermore, there were no significant differences in the rates of complete response (RR = 1.05, 95% CI [0.97, 1.13]) , partial response (RR = 0.74, 95% CI [0.49, 1.12]) , or no response (RR = 0.97, 95% CI [0.57, 1.65]). Adverse events showed no significant difference between the treatments (RR = 0.97, 95% CI [0.57, 1.65]). Similarly, the risk of progressing to ESRD requiring dialysis was not significantly different between the MMF and CYC groups (RR = 1.28, 95% CI [0.28, 5.85]).
Conclusion
MMF and CYC demonstrate comparable efficacy and safety profiles. Treatment with MMF does not yield statistically significant differences in renal function (eGFR), clinical response, remission rates, adverse events, or progression to ESRD when compared to CYC.